Saudi Arabia Influenza Vaccine Market Report and Forecast 2026-2034

Study Period

2021-2034

Market (2026)

USD 33.20 Million

Market (2034)

USD 61.00 Million

CAGR

7.90%

Major Markets Players

GlaxoSmithKlineplc., AbbottS.A., AstraZeneca PLC, Merck Limited, Johnson and Johnson Medical Saudi Arabia Limited and Others

*Note: Partial List Randomly Ordered

Saudi Arabia Influenza Vaccine Market Statistics and Insights

Saudi Arabia Influenza Vaccine Market Insights & Analysis

The Saudi Arabia Influenza Vaccine Market is anticipated to register a 7.90% CAGR during 2026–2034. The market size was valued at USD 33.20 million in 2026 and is projected to reach USD 61.00 million by 2034. The Ministry of Health (MOH) plays an instrumental role in promoting influenza vaccination initiatives, particularly targeting high-risk groups such as the elderly, pregnant women, and those with chronic diseases. A pivotal development reinforcing this growth trajectory occurred in October 2025, when CSL Seqirus, Vaccine Industrial Company, and Saudi Arabia's Ministry of Health signed a landmark Memorandum of Understanding to localize manufacturing of cell-based seasonal and pandemic influenza vaccines at VIC's new Sudair City facility, marking the Kingdom's first onshore flu vaccine manufacturing initiative.

The Saudi government allocates over SAR 200 million (approximately USD 53 million) annually to support influenza vaccination programs, aiming to vaccinate high-risk populations including children and the elderly. Post-pandemic healthcare consciousness, expanding digital health infrastructure, and Vision 2030's preventive medicine mandate are collectively accelerating market expansion with remarkable consistency across both public and private healthcare channels.

Saudi Arabia Influenza Vaccine Market Dynamics

Key Market Driver Hajj-Driven Seasonal Vaccination Surge

Saudi Arabia's role as the epicenter of annual Hajj and Umrah pilgrimages creates a uniquely recurring and structurally embedded driver for influenza vaccine demand. Influenza can cause up to 6.3 million mild to moderate cases, 17,600 hospitalizations, and 4,440 deaths annually in Saudi Arabia, and in 2024, 96% of intensive care patients admitted with influenza had not been vaccinated. The mass congregation of pilgrims from over 180 nations intensifies transmission risk, compelling the Ministry of Health to scale up immunization drives year-on-year. The Ministry of Health reports approximately 1.5 million influenza cases annually, with rising urbanization and population density further facilitating virus transmission. This religiously anchored epidemiological pressure generates a consistent, government-mandated demand cycle that few other regional markets can replicate.

Major Industry Challenge Cold Chain Integrity Across Distribution Networks

Any disruption in the cold chain can lead to reduced vaccine potency, rendering doses ineffective and causing vaccine wastage, while the cost of managing these logistical hurdles increases the overall expenses associated with vaccine distribution. Saudi Arabia's vast geographic terrain, spanning arid desert regions, mountainous zones, and remote communities, creates persistent cold-chain management difficulties. Influenza vaccines are typically developed annually based on predicted strains for the upcoming flu season, meaning they have a short window of use, and healthcare providers must manage inventory carefully to avoid expiration, which can lead to financial losses and decreased vaccine availability. Bridging urban-rural distribution disparities requires substantial investment in temperature-controlled infrastructure and last-mile logistics, which remains an ongoing challenge for both public health authorities and private pharmaceutical distributors operating across the Kingdom.

Emerging Trend Shaping Outlook Cell-Based Vaccine Localization and Onshore Manufacturing

A transformative trend reshaping the Saudi Arabia Influenza Vaccine Market is the strategic shift toward domestic vaccine manufacturing. CSL Seqirus and Vaccine Industrial Company signed a landmark MOU with the Ministry of Health to localize manufacturing of cell-based influenza vaccines at VIC's Sudair City facility, with ambitions to establish pandemic preparedness in 2026 and supply cell-based flu vaccines for the 2026/27 flu season. Saudi Arabia allocated SAR 10 billion toward establishing manufacturing facilities for key vaccines, with partnerships fostering technology transfer and building local expertise. Cell-based manufacturing eliminates egg-adaptation mutations, yielding vaccines with superior strain-matching accuracy. This localization push reduces import dependency, supports Vision 2030's bioeconomy ambitions, and positions Saudi Arabia as a future regional vaccine hub for MENA markets.

Saudi Arabia Influenza Vaccine Market Segment-wise Analysis

The Saudi Arabia Influenza Vaccine Market is segmented by Vaccine Type and Distribution Channel, with each segment reflecting distinct demand patterns, regulatory priorities, and end-user behaviors. Understanding these segments is critical for stakeholders seeking to align product portfolios, distribution strategies, and investment decisions with prevailing market realities across the Kingdom's evolving healthcare landscape.

By Vaccine Type

• Inactivated Influenza Vaccine
• Live Attenuated Influenza Vaccine

Inactivated influenza vaccines lead market growth due to their broad suitability and safety for diverse populations. This sub-segment commands approximately 72% of the total vaccine type segment revenue in 2026, owing to its established clinical profile, regulatory acceptance, and compatibility across all age groups, including immunocompromised individuals. The trivalent inactivated vaccine (TIV) remains the Ministry of Health's preferred tool for national immunization programs, particularly for mass campaigns during Hajj season. Live Attenuated Influenza Vaccine (LAIV) accounts for the remaining 28% market share, with growing uptake in pediatric applications as the MOH expands childhood immunization coverage. LAIV's needle-free nasal administration offers an advantage in improving compliance among children and vaccine-hesitant adults. As next-generation quadrivalent and cell-based inactivated formulations gain regulatory traction, the Inactivated segment is projected to consolidate its dominance through the forecast period.

By Distribution Channel

• Hospital
• Retail Pharmacies
• Government Suppliers
• Others

Hospitals have become key vaccination centers, offering convenient access to immunizations and playing a significant role in the market's expansion. The hospital channel holds approximately 48% of distribution revenue in 2026, driven by centralized seasonal vaccination campaigns, high patient throughput during flu season, and the integration of influenza vaccination into routine clinical care pathways. Hospitals remain the fastest-growing segment due to centralized vaccination campaigns and high patient throughput. Government Suppliers represent approximately 28% share, acting as the backbone of national immunization programs that distribute free vaccines to high-risk populations through primary healthcare centers (PHCs) and mobile units. Retail Pharmacies account for 18%, with urban pharmacies in Riyadh, Jeddah, and Dammam increasingly offering walk-in flu shots, particularly to the working-age expatriate population. The Others segment (6%) includes home vaccination services and corporate occupational health programs.

Regional Projection of Saudi Arabia Influenza Vaccine Market

The Saudi Arabia Influenza Vaccine Market exhibits strong regional variation driven by healthcare infrastructure density, population size, and proximity to pilgrimage centers.

• Northern & Central Region
• Western Region
• Eastern Region
• Southern Region
• Northern Borders Region

Northern and Central Saudi Arabia, including Riyadh, dominate the market, facilitated by healthcare services linked to religious pilgrimages and strong private sector engagement. This region captures approximately 42% of the overall market share, supported by Riyadh's advanced hospital infrastructure, government headquarters overseeing national vaccination policy, and large-scale immunization logistics networks. The Western Region ranks second, fueled by the annual Hajj influx that drives seasonal vaccine demand spikes. Eastern Region's industrial base and expatriate workforce sustain steady year-round vaccination uptake across Dammam and Dhahran.

Saudi Arabia Influenza Vaccine Market: Recent Development (2025)

• In October 2025, CSL Seqirus and Vaccine Industrial Company signed a landmark MOU with Saudi Arabia's Ministry of Health to localize cell-based influenza vaccine manufacturing at VIC's Sudair City facility, targeting the 2026/27 flu season for initial supply rollout.
• GlaxoSmithKline plc. reported global vaccine segment revenues exceeding USD 8.2 billion in 2024, with its Fluarix and FluLaval products maintaining strong prescription market share in the Middle East and Africa region, supporting double-digit percentage revenue growth from Gulf markets.
• AstraZeneca PLC continued expanding its Saudi Arabia operations in 2025, with its MENA business unit reporting approximately 18% year-over-year revenue growth, driven partly by respiratory disease vaccine and biologics portfolios aligned with MOH preventive care guidelines.
• Abbott S.A. reinforced its distribution network across Saudi Arabia's retail pharmacy and hospital channels in 2025, leveraging its diagnostics-vaccine bundled service model to increase influenza vaccine penetration in corporate occupational health programs across the Eastern Province.

Saudi Arabia Influenza Vaccine Market Future Outlook (2034)

The Saudi Arabia Influenza Vaccine Market is poised for robust expansion, projected to grow at a CAGR of 7.90% from 2026 to 2034, reaching USD 61.00 million by the end of the forecast period. Key growth opportunities include the commercialization of domestic cell-based vaccine manufacturing by 2028, the integration of AI-powered epidemiological surveillance for strain prediction, and the expansion of quadrivalent vaccine adoption across both pediatric and adult segments. Vision 2030's bioeconomy pillar, combined with Saudi Arabia's preparations to host FIFA World Cup 2034 and World EXPO, will necessitate strengthened pandemic preparedness frameworks, directly fueling public and private investment in influenza immunization infrastructure through the decade.

Saudi Arabia Influenza Vaccine Market Report Coverage

Why Choose This Report?

• Provides a comprehensive overview of the overall market analysis, encompassing key trends, consumer behavior analysis, and risk assessment to support strategic decision-making.
• Provides accurate, up-to-date insights into market size, segmentation, and emerging opportunities, helping to minimize risk & capitalizing on growth.
• Gives deep understanding of target audience preferences, investment habits, and communication channels for enhanced product development & marketing effectiveness.
• Delivers competitive analysis & benchmarking, uncovering the strengths & weaknesses of market competitors to guide strategies.
• Consolidate comprehensive market intelligence, reducing reasoning & streamlining research efforts.
• Facilitates customized market segmentation & risk mitigation strategies, fine-tuned to the business objectives.
• Aids in identifying both market challenges & untapped opportunities within the industry to drive long-term business growth.
• Provides valuable information based on actual customer data & search trends.